AZAFAROS B.V.

AZAFAROS B.V. is a clinical-stage biotechnology company founded in 2018, based in Naarden, Netherlands, with operations in Leiden and Basel, Switzerland.

The company specializes in developing oral, disease-modifying small molecule therapeutics for patients with severe rare genetic lysosomal storage disorders that affect the central nervous system. Led by a team of experienced industry professionals, AZAFAROS aims to create new treatment options for life-threatening metabolic conditions where effective therapies are currently lacking. The company's lead clinical-stage program, Nizubaglustat (also known as AZ-3102), is an orally available small molecule that targets key disease pathways by interfering with glycosphingolipid metabolism. It is designed to treat conditions such as GM1 and GM2 gangliosidoses and Niemann-Pick disease type C. AZAFAROS is committed to patient-centric innovation, focusing on rapidly developing therapeutics for rare diseases and translating academic research into commercial solutions.